PRLog Home
All Businesses
All Newsrooms
Press Releases Home
sfbanc financial
About
Newsroom
Contact
Filter By Industry
Select One
Biotech
Filter By Tag
Select One
Biotech
Newsroom
sfbanc financial Press releases
1 - 1 of 1 Press Release
Cassava Sciences (SAVA) Upgraded to Strong Buy by sfbanc
Aug 26, 2022
Simufilam is a leading candidate to become the first effective treatment for Alzheimer's Disease. In an analysis by sfbanc financial, Cassava Sciences, Inc. (SAVA) was upgraded as a Strong Buy, from 8/10 to 9.5/10.
sfbanc financial RSS Feed
Share This Page
Website